Efficacy of onabotulinumtoxinA treatment in episodic migraine.

Background: OnabotulinumtoxinA (BoNT-A) is approved as a prophylactic treatment of chronic migraine (CM) only. We aimed to assess the efficacy and safety of BoNT-A in the treatment of episodic migraine (EM).

Methods: This is a prospective study included migraine patients, aged 18-65 years, and completed 1 year treatment with BoNT-A.

Pediatric onset multiple sclerosis in Kuwait.

Background: Epidemiological data of pediatric-onset multiple sclerosis (POMS) in the Middle East is limited.

Objective: To determine the demographic and clinical characteristics of POMS in Kuwait.

Methods: A retrospective study was conducted to assess the clinical characteristics of multiple sclerosis (MS) patients who disease onset started at age < 18 years and fulfilled the International Pediatric MS Study Group (IPMSSG) criteria for MS.

Real world study of ocrelizumab in multiple sclerosis: Kuwait experience.

Background: Ocrelizumab is a humanized anti-CD20 antibody that has been approved for the treatment of patients with multiple sclerosis (MS). Real-world data in the Middle East is very limited.

Objectives: To describe the effectiveness and safety of ocrelizumab treatment in MS patients in a real clinical setting.

A prospective observational longitudinal study with a two-year follow-up of multiple sclerosis patients on Cladribine.

Background: Cladribine was approved for the treatment of multiple sclerosis (MS). Real-world data is very limited.

Objectives: To study the effectiveness and the safety of Cladribine treatment in only one group of MS patients after treatment with Cladribine for two years.

A real-life study of alemtuzumab in persons with multiple sclerosis: Kuwait's experience.

Background: Alemtuzumab, a humanized anti-CD52 monoclonal antibody, has been approved as a treatment in persons with active relapsing-remitting multiple sclerosis (RRMS). Real-world data in middle east is very limited. We aimed to evaluate the effectiveness and safety of alemtuzumab in a real-world clinical setting.

Complications Post Abdominoplasty After Surgical Versus Non-surgical Massive Weight Loss: a Comparative Study.

Purpose: This study aims to investigate the rate of short- and long-term complications as well as the need for operative revisions after abdominoplasty for patients following surgical versus non-surgical weight loss methods.

Methods: This is a retrospective chart review that enrolled consecutive patients undergoing abdominoplasty across a 5-year period, aged 18 years and above, opting for abdominoplasty after weight loss achieved through bariatric surgery or diet and exercise alone.

Results: A total of 364 patients lost weight through bariatric surgery and 106 by diet and exercise alone.

COVID-19 vaccination in people with multiple sclerosis, real-life experience.

Background: Vaccination against the severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2) virus is recommended in multiple sclerosis (MS) to reduce the risk of complications from Coronavirus disease 2019 (COVID-19) infection. These vaccines were not investigated in people with MS (PWMS).

Objective: This study aimed to report the short-term safety of the COVID-19 vaccines among PWMS.